Current Clinical Research Projects at Our Clinic
AriBio Co. Ltd.
Protocol: AR1001-ADP3-US01
Patients: 55-90 years old
Diagnostic: Early AD
Agent: AR1001
Daily Oral Administration
Enrollment: OPEN
Cognito Therapeutics, Inc
Protocol: CA-0011
Patients: 50-90 years old
Diagnostic: Mild-Moderate AD
Agent: Medical Device
Worn Daily for 1 Hour
Enrollment: OPEN
Alector Inc.
Protocol: AL002-2
Patients: 50-85 years old
Diagnostic: Early Alzheimer’s disease
Agent: AL002
Intravenous Administration Every 4 Weeks
Enrollment: Closed
Alzheon Inc.
Protocol: ALZ-801-AD301
Patients: 50-80 years old
Diagnostic: Early Alzheimer’s disease
Agent: ALZ-801
Twice Daily Oral Administration
Enrollment: Closed
Athira Pharma Inc.
Protocol: ATH-1017-AD-0201
Patients: 55-85 years old
Diagnostic: Probable Mild-Moderate AD
Agent: ATH-1017
Daily Subcutaneous Injection
Enrollment: Closed
Athira Pharma Inc.
Protocol: ATH-1017-AD-0202
Patients: 55-85 years old
Diagnostic: Probable Mild-Moderate AD
Agent: ATH-1017
Daily Subcutaneous Injection
Enrollment: Closed
Cassava Sciences Inc.
Protocol: PTI-125-06
Patients: 50-87 years old
Diagnostic: Alzheimer’s disease (Stage 4 or 5)
Agent: Simufilam (PTI-125)
Twice Daily Oral Administration
Enrollment: Closed
EIP Pharma Inc.
Protocol: EIP21-NFD-504
Patients: 55 years old and above
Diagnostic: Dementia with Lewy Bodies (DLB)
Agent: Neflamapimod
Daily Oral Administration
Enrollment: Closed
Eli Lilly and Company
Protocol: I5T-MC-AACM
Patients: 65-80 years old
Diagnostic: Prodromal/Asymptomatic AD
Agent: Donanemab
Intravenous Administration Every 4 Weeks
Enrollment: Closed
Eli Lilly and Company
Protocol: I5T-MC-AACI
Patients: 60-85 years old
Diagnostic: Prodromal or Mild AD Dementia
Agent: Donanemab
Intravenous Administration Every 4 Weeks
Enrollment: Closed
Eli Lilly and Company
Protocol: J1G-MC-LAKC
Patients: 60-85 years old
Diagnostic: Prodromal/Asymptomatic AD
Agent: Remternetug
Subcutaneous Injection
Enrollment: Closed
Novo Nordisk
Protocol: NN6535-4730
Patients: 55-85 years old
Diagnostic: Early Alzheimer’s disease
Agent: Semaglutide
Once Daily Oral Administration
Enrollment: Closed
Novo Nordisk
Protocol: NN6535-4725
Patients: 55-85 years old
Diagnostic: Early Alzheimer’s disease
Agent: Semaglutide
Once Daily Oral Administration
Enrollment: Closed